Daratumumab is a human CD38-directed monoclonal antibody approved in the United States as monotherapy for patients with multiple myeloma (MM) who have received 3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD, and in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone for patients with MM who have received 1 prior LOT. This study compared the efficacy of daratumumab monotherapy versus historical controls through adjusted treatment comparison. Patient-level data were pooled from two daratumumab monotherapy studies (16 mg/kg; GEN501 and SIRIUS) and two independent US databases (IMS LifeLink and OPTUM), which reflect treatments used in real-world patients with MM who received 3 prior LOTs or were double refractory to a PI and an IMiD. Using a multivariate proportional hazards regression model, the relative treatment effect of daratumumab versus historical controls was estimated, adjusting for imbalances in characteristics between cohorts. Baseline characteristics that differed between patients treated with daratumumab (N 5 148) and historical control (N 5 658) were prior treatment with pomalidomide (55% vs 15%) or carfilzomib (41% vs 28%) and triple/ quadruple refractory status (64% vs 14%). The adjusted overall survival-hazard ratio (OS-HR) for daratumumab versus historical control was 0.33 (95% confidence interval, 0.24-0.46) compared with 0.46 (0.35-0.59) for unadjusted HR. Impact of adjustment was mainly driven by refractory status and prior pomalidomide/carfilzomib exposure. This adjusted treatment comparison suggests that daratumumab demonstrates improved OS compared with historical control data in heavily pretreated and highly refractory MM patients.
| I N T R O D U C T I O N
Comparative assessments of new agents for the treatment of heavily pretreated patients with relapsed and refractory multiple myeloma (MM) who have exhausted approved treatment options are challenging, as active-controlled studies are not feasible because there are no generally accepted standard regimens to use for comparison. In the absence of head-to-head data, it is important to understand treatment outcomes based on current real-world experience in a routine clinical setting to fully recognize the potential benefits of novel agents. These outcomes data may be used as a benchmark and can provide evidence beyond that collected during clinical development in randomized controlled trials. Historical controls may provide useful information for both clinicians and reimbursement decision makers and may serve as a reference point against which newer agents can be evaluated. 1 Daratumumab is a first-in-class human IgG1 monoclonal antibody that binds CD38, which is highly and ubiquitously expressed on myeloma cells. [2] [3] [4] Daratumumab-induced on-tumor activity occurs through several CD38 immune-mediated actions (eg, complementdependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis), apoptosis, and modulation of CD38 enzymatic activity. [5] [6] [7] [8] This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. LOTs that included a PI and an IMiD. In SIRIUS, patients were relapsed from or refractory to at least 3 prior LOTs that included a PI or an IMiD or were double refractory to a PI and an IMiD.
| Study designs
Study methodology and primary results from the GEN501 and SIRIUS studies have been described in detail elsewhere. 14, 15 Briefly, GEN501
was an open-label, phase 1/2, dose-escalation and dose-expansion study, 14 and SIRIUS was an open-label, multicenter, phase 2 study. 15 
| Endpoints
For patients identified in the IMS LifeLink or OPTUM databases, OS from the start of the last LOT was defined based on death or loss to follow-up more than 30 days prior to the study end date. For patients in the GEN501 and SIRIUS studies, OS was defined as the number of days from the first dose of daratumumab to death.
| Adjusted treatment comparison
The relative treatment effect of daratumumab was estimated using patient-level data from the historical controls (US claims databases) and clinical studies (pooled analysis of patients receiving daratumumab 16 mg/kg in GEN501 Part 2 and SIRIUS).
Analysis of OS was conducted on the intention-to-treat population from both cohorts using Kaplan-Meier analysis and Cox proportional hazards regression. Statistical adjustments were made using patientlevel data, assuming no unobserved confounders. To avoid confounding bias, multivariate proportional hazards regression modeling was used to estimate the hazard ratio (HR) of daratumumab versus physician's choice as a measure of relative efficacy/effectiveness for time to event data to account for the differences in patient characteristics between the daratumumab trials and data from the US claims data- which pooled data from GEN501 and SIRIUS were compared with outcomes in heavily pretreated patients from other data sources. 22 The results from this study must be considered within the confines of its inherent limitations. Although a range of clinically relevant prognostic factors were available and adjusted for, residual confounding bias cannot be excluded, as in any observational study. Additionally, because the historical control data were extracted from claims databases, certain data were missing or could have been inaccurately coded during data entry, whereas the daratumumab data were derived from registered clinical trials and validated by the study sites, the sponsor, This study is also limited by the differences between the claims database and clinical trial populations. Records collected from the US databases described patients treated between 2000 and 2014, whereas daratumumab-treated patients were treated more recently and, thus, are more likely to have had access to different treatment regimens than some of the patients in the historical US cohort. It is possible that the access to newer regimens may have enhanced the apparent survival benefit of daratumumab treatment. However, as the daratumumab cohort included patients who had already received, and relapsed on, these newer regimens, this instead may bias the results toward a lower OS in daratumumab-treated patients. Additionally, daratumumab confers a survival benefit, even to patients with MR and SD, 10 suggesting that the survival benefit is due to daratumumab rather than to subsequent therapies. The daratumumab cohort also had a lower median age than the claims database cohort (64 vs 69 years, respectively), which could potentially bias the results toward a benefit to OS for the daratumumab group. However, the daratumumab group had received a greater median number of prior LOTs (5 vs 4, respectively) and had a higher proportion of triple/quadruple refractory patients (64% vs 14%, respectively), both factors that would be expected to have a negative impact on OS. With the exception of access to newer treatment regimens, all of these potentially confounding factors (age, LOTs, and refractory status) were adjusted for in the multivariate model.
In summary, this adjusted treatment comparison suggests that daratumumab monotherapy provides a substantial survival benefit compared with real-world historical controls in patients with heavily pretreated and highly refractory MM. In the absence of head-to-head clinical trials, comparative analyzes adjusting for differences in patient characteristics using patient-level data can provide valuable insights to clinicians and reimbursement decision makers on the relative efficacy of daratumumab versus established standard of care treatments.
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